The Clinical TIL Experience in Melanoma: Past, Present, Future
- PMID: 40089331
- DOI: 10.1016/j.jtct.2024.11.013
The Clinical TIL Experience in Melanoma: Past, Present, Future
Abstract
The recent approval of lifileucel by the US Food and Drug Administration in February 2024 was the culmination of over 3 decades of research in adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) for unresectable melanoma. In this review, we highlight key historical data for TIL therapy in melanoma as well as ongoing efforts to improve its efficacy and applicability.
Keywords: Autologous; Immunotherapy; Melanoma; Tumor infiltrating lymphocytes.
Copyright © 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
